Antioxidant and hepatic fibrosis-alleviating effects of selenium-modified Bletilla striata polysaccharide

  • 0National Engineering Laboratory for Resource Development of Endangered Crude, Drugs in Northwest China, Shaanxi Normal University, Xi'an 710119, China; Key Laboratory of Medicinal Resources and Natural Pharmaceutical Chemistry (Shaanxi Normal University), The Ministry of Education, Xi'an 710119, China; College of Life Sciences, Shaanxi Normal University, Xi'an 710119, China.

|

|

Summary

This summary is machine-generated.

Modified Bletilla striata polysaccharide (Se-BSP) shows improved efficacy in treating liver fibrosis. This study provides a basis for Se-BSP as a potential therapeutic agent for liver fibrosis.

Area Of Science

  • Pharmacology
  • Biochemistry
  • Hepatology

Background

  • Liver fibrosis is a critical precursor to cirrhosis and liver cancer.
  • Current treatments for liver fibrosis are limited.
  • Bletilla striata polysaccharide (BSP) shows therapeutic potential but is less effective at medium concentrations.

Purpose Of The Study

  • To structurally characterize selenized BSP (Se-BSP).
  • To evaluate the in vivo efficacy of Se-BSP in alleviating liver fibrosis.
  • To improve the therapeutic performance of BSP at medium concentrations.

Main Methods

  • Selenization modification of Bletilla striata polysaccharide (BSP).
  • Structural characterization of selenized BSP (Se-BSP).
  • In vivo evaluation of Se-BSP's anti-fibrotic activity in a liver fibrosis model.

Main Results

  • Selenization increased the molecular weight of BSP.
  • Se-BSP demonstrated enhanced in vitro antioxidant activity.
  • Se-BSP showed improved efficacy in alleviating liver fibrosis at 150 mg/kg compared to BSP.

Conclusions

  • Se-BSP exhibits enhanced anti-fibrotic properties compared to native BSP.
  • The modified polysaccharide offers a promising therapeutic strategy for liver fibrosis.
  • Se-BSP provides a theoretical basis for its application as an anti-liver fibrosis agent.